SEC Comment Letter for Tempest Therapeutics, Inc. (TPST) (CIK 0001544227) (TPST) — Jul 17, 2012
Tempest Therapeutics, Inc. (TPST) (CIK 0001544227)
Date: July 17, 2012 · CIK: 0001544227 · Accession: 0000000000-12-037418
AI Filing Summary & Sentiment
Show Raw Text
July 17 , 2012 Via E -mail Christopher Bleck Chief Operating Officer OvaScience, Inc. 800 Boylston Street, Suite 1555 Boston, Massachusetts 02199 Re: OvaScience, Inc. Registration Statement on Form 10-12G Filed April 11, 2012 File No. 000 -54647 Dear Mr. Bleck : We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We u rge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey Riedler Jeffrey Riedler Assistant Director cc: Lia Der Marderosian, Esq. WilmerHale 60 State Street Boston , MA 02109